MDL 28170

Drug Profile

MDL 28170

Latest Information Update: 03 Jul 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aventis
  • Class Anti-ischaemics; Neuroprotectants
  • Mechanism of Action Calpain inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cataracts; Cerebral ischaemia; Neurological disorders

Most Recent Events

  • 10 May 2000 Preclinical development for Cataracts in Germany (Unknown route)
  • 10 May 2000 A preclinical study has been added to the Eye Disorders pharmacodynamics section
  • 01 May 2000 No-Development-Reported for Cerebral ischaemia in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top